drugset / Trial / NCT00739349

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

NCT00739349 ↗

Phase 2 Completed 132 enrolled Santen SAS
RandomizedParallel-groupDouble-blindTreatment

Summary

Study is to assess the safety and efficacy of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions QD compared to vehicle for the treatment of the signs and symptoms of dry eye after a 3 month treatment period.

Timeline

Start
2008-08
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NOVA22007 Unknown 0.05 % Other
Subject NOVA22007 Unknown 0.1 % Other

Indications